SCHEMBL2326527

SCHEMBL2326527

CC(=O)c1ccc(-c2sc(NC(=O)n3ccnc3)nc2C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 14/20 0.65
PIK3CG P48736 14/20 0.65
PIK3CA P42336 13/20 0.65
PIK3CB P42338 12/20 0.65
PI4KB Q9UBF8 2/20 0.50
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
XIAP P98170 1/20 0.44
PPARG P37231 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
CLK1 P49759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1885511 0.89 PIK3CD (0.47) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1786172 0.85 PIK3CD (0.65) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL13149722 0.83 PIK3CD (0.49) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1882046 0.83 PIK3CA (0.43) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL12991700 0.82 PIK3CG (0.51) PIK3CDPIK3CGPIK3CAPIK3CBNPC1
SCHEMBL13149663 0.82 PIK3CD (0.72) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL29089052 0.81 PIK3CG (0.39) PIK3CDPIK3CGPIK3CAPIK3CBNPC1
SCHEMBL13469237 0.80 PIK3CA (0.48) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL1889405 0.80 PIK3CA (0.50) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB
SCHEMBL48942 0.79 PIK3CG (1.00) PIK3CDPIK3CGPIK3CAPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357179-A1 Thiazol-2-yl organic compounds Novartis AG (CH) 2011-08-17 EP disclosed
US-7799810-B2 Organic compounds NOVARTIS AG (CH) 2010-09-21 US disclosed
US-7799810-B2 Organic compounds NOVARTIS AG (CH) 2010-09-21 US disclosed
US-20100120865-A1 Organic compounds NOVARTIS AG (CH) 2010-05-13 US disclosed
US-20100120865-A1 Organic compounds NOVARTIS AG (CH) 2010-05-13 US disclosed
WO-2008000421-A2 THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120865-A1 Organic compounds PIK3C3, PIK3R3, PIK3R4 PIK3CD 10/4885PIK3CG 12/4885PIK3CA 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.